<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02663115</url>
  </required_header>
  <id_info>
    <org_study_id>U1111-1178-1176</org_study_id>
    <nct_id>NCT02663115</nct_id>
  </id_info>
  <brief_title>Influence of Severe Heart Failure to Function and Molecular Biological Parameters of Catabolism in the Human Diaphragm and Peripheral Skeletal Muscle</brief_title>
  <acronym>LIPAMUS-HF</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Norman Mangner</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heartcenter Leipzig GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Project aim is to quantify the influence of a severe therapy-refractory heart failure caused
      by ischemic or dilative myocardiopathy on the function of the diaphragm, its molecular
      biological parameters and on the M. vastus lateralis. The control group consists of patients
      with coronary artery disease (CAD) and normal left ventricular ejection fraction indicated
      for coronary artery bypass graft surgery (CABG) Differences in the geneses of heart failure
      (ischemic vs. dilative cardiomyopathy) will be evaluated during analysis. The
      ubiquitin-proteasome signaling pathway is considered as a central issue for the mechanism of
      the analyses muscle catabolism.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Expression of catabolic E3 ligase Muscle ring finger 1 (MuRF1)</measure>
    <time_frame>at the time of index procedure (biopsy)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>in vitro measurement of the muscle protein - poly ubiquitination of Proteins</measure>
    <time_frame>at the time of index procedure (biopsy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>in vitro measurement of the muscle protein - the proteasome activity</measure>
    <time_frame>at the time of index procedure (biopsy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>in vitro measurement of the muscle protein - fiber typing in the muscle samples</measure>
    <time_frame>at the time of index procedure (biopsy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>in vitro measurement of the force development of skinned muscle fibers</measure>
    <time_frame>at the time of index procedure (biopsy)</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Heart Failure</condition>
  <condition>Ischemic Myocardiopathy</condition>
  <condition>Dilatative Myocardiopathy</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <description>Patients (age 40 - 70 years) with severe therapy-refractory heart failure caused by ischemic myocardiopathy with indication for left ventricular assist device (LVAD) therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <description>Patients (age 40 - 70 years) with severe therapy-refractory heart failure caused by dilatative myocardiopathy with indication for left ventricular assist device (LVAD) therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <description>Patients (age 40-70 years) with the indication for elective bypass surgery and normal left ventricular function (EF&gt;50%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biopsy of the diaphragmatic muscle</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Skeletal muscle biopsy</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe therapy-refractory heart failure
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        inclusion criteria Group A:

          -  age 40 - 70 years

          -  Restricted left ventricular pump function left ventricular ejection fraction (LVEF) &gt;
             35% on the basis of ischemic cardiomyopathy (ICM) and restricted resting cardiac
             output (CI&gt; 2.4 L / min / m²)

          -  or restricted maximal oxygen uptake (VO2max&gt; 17 ml / min / m²)

          -  Duration of heart failure&gt; 1 year

          -  Maximum of individual heart failure therapy

          -  Heart team decision to LVAD Implantation

        inclusion criteria Group B:

          -  age 40 - 70 years

          -  Restricted left ventricular pump function (LVEF) &gt; 35% on the basis of dilatative
             cardiomyopathy (DCM) and restricted resting cardiac output (CI&gt; 2.4 L / min / m²)

          -  or restricted maximal oxygen uptake (VO2max&gt; 17 ml / min / m²)

          -  Duration of heart failure&gt; 1 year

          -  Maximum of individual heart failure therapy

          -  Heart team decision to LVAD Implantation

        inclusion criteria Group C:

          -  age 40 - 70 years

          -  coronary heart disease with indication for elective, coronary artery bypass surgery

          -  normal left ventricle (LV) pumping function LVEF&gt; 50%

          -  stable clinical situation (no cardiac decompensation within the last 6 months)

        Exclusion Criteria:

          -  Mechanical ventilation within the last 3 months

          -  Forced Expiratory Pressure (FEV1) &lt;70% of the norm and / or therapy with α
             antagonists, β-mimetics or inhaled corticosteroids for the treatment of a lung disease

          -  Pulmonary fibrosis

          -  elevated diaphragm in the ultrasound or X-ray diagnosis or known paresis of the
             phrenic nerve

          -  chronic kidney disease (CKD) stage 4 and 5, i.e. glomerular filtration rate (GFR)
             &lt;30ml / min / 1.73m and / or dialysis

          -  Acute renal failure

          -  Treatment with immunosuppressive agents

          -  Hepatic insufficiency Child-Pugh B and C

          -  Higher grade ventricular arrhythmias (Lown IV b)

          -  Acute myocardial infarction (less than three months)

          -  Decompensated Vitium cordis

          -  Age &lt;40 years and&gt; 70 years

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Norman Mangner, MD</last_name>
    <email>norman.mangner@medizin.uni-leipzig.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Heart Center Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norman Mangner, MD</last_name>
      <email>norman.mangner@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2016</study_first_submitted>
  <study_first_submitted_qc>January 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <last_update_submitted>August 15, 2016</last_update_submitted>
  <last_update_submitted_qc>August 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Heartcenter Leipzig GmbH</investigator_affiliation>
    <investigator_full_name>Norman Mangner</investigator_full_name>
    <investigator_title>Dr. med. Norman Mangner</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

